|Bid||18.96 x 800|
|Ask||18.99 x 1000|
|Day's Range||18.79 - 20.27|
|52 Week Range||10.22 - 30.25|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Evolus, Inc. makes a product that is a competitor to Botox, and since I am on the wrong side of 65 I thought I would take a look at the charts and indicators. In this daily bar chart of EOLS, below, you can see that prices have swung up and down and back and forth. Trading volume has been light with a couple of volume surges in February and again in May. The On-Balance-Volume (OBV) line moved up sharply in January and February and it has given back about half of the gains, suggesting that many of the recent longs are still holding their positions.
AbbVie's (ABBV) stock suffers a poor run on the bourses due to pipeline setbacks, Humira sales erosion in EU and its proposed offer to buy Allergan.
Taking the occasional loss comes part and parcel with investing on the stock market. And unfortunately for Evolus...
In the daily bar chart of EOLS, below, we can see some choppy up and down trading -- not all that unusual for a relatively recent IPO. The On-Balance-Volume (OBV) line shows a couple trends over the past twelve months -- a decline to December followed by a very steep rise in early February and then another decline. In recent weeks the OBV line has been steady, which may be signaling a return of more aggressive buyers.
Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.
(Bloomberg Opinion) -- When the maker of the top-selling arthritis drug says it’s buying a leader in anti-wrinkle treatments, you’d be forgiven if your initial response to the news was that it seems like a match made in heaven. But take a closer look, and AbbVie Inc.’s $63 billion purchase of Botox maker Allergan Plc isn’t such a perfect fit. AbbVie is desperate for diversification as sales of its $19 billion arthritis blockbuster Humira begin to slow; in Allergan, it has the opportunity acquire a rival at a relative bargain. Even at a 45% premium to Allergan’s closing share price Monday, AbbVie is paying a fraction of what the drugmaker was worth just a couple of years ago, and Botox is still growing.The deal is projected to net big synergies: AbbVie projects cost savings from the combination will plump up its bottom line by $2 billion within three years. But AbbVie's most significant problem isn't the next few years. It's figuring out how to grow when Humira's sales take a real dive starting in 2023. It’s not clear that Allergan will be much help there, and the early reaction from AbbVie shareholders suggests they have doubts:The long-term outlook for Botox is a matter of debate. The toxin, which is used to both smooth wrinkles and treat migraines, has impressive brand recognition and a solid grip on the market. But a cheaper competitor on the market from Evolus Inc. was recently approved, and another from Revance Inc. has produced compelling data and is on the way.On top of that, there’s a new class of preventative migraine drugs on the market, which could pressure Botox’s market share from a different angle. Botox has held up so far. But these pressures are only going to increase over time, and its best days of growth are likely in the past. There’s a decent chance that its sales will flatten just as Humira’s begin to crater when biosimilar copycats hit the U.S. market in 2023.Then there’s the question of what AbbVie gets outside of Botox from Allergan’s pharmaceutical business. The fit is questionable; AbbVie is principally focused on cancer and drugs for inflammatory conditions like arthritis. Allergan doesn’t add anything significant there. So is the quality. Aging products, questionable deals, and research failures have battered Allergan’s stock to the point where investors have been calling for a breakup of the company or a change in management. Allergan has a few growing marketed products, including gastrointestinal drug Linzess and anti-psychotic treatment Vraylar. But there’s little in its late-stage development pipeline to get excited about, especially given its poor recent track record in R&D. Allergan adds little in the way of the research capability required to discover new medicines, and that’s by design. The company has deliberately focused on acquiring assets that others have developed. AbbVie’s acquisition track record since it separated from Abbott Laboratories in 2013 is shaky. Pharmacyclics Inc. netted it half of a good cancer drug at a bruising price, and its $5.8 billion acquisition of Stemcentrx Inc. looks like a complete flop. The company’s biggest deal yet may not improve its reputation.To contact the author of this story: Max Nisen at email@example.comTo contact the editor responsible for this story: Beth Williams at firstname.lastname@example.orgThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Evolus, Inc. (NASDAQ:EOLS) should be aware of the most powerful shareholder groups...
Within Pharmacy Services, despite a fierce pricing competition, CVS Health (CVS) is currently riding on high level of service and execution, competitive pricing and a unique integrated model.
These three health and technology stocks are seeing technical strength ahead of upcoming earnings. Evolus, Inc. (NASDAQ: EOLS ) gained 50 cents to $26.44 on 537,100 shares Wednesday. The performance beauty ...
Evolus Inc. (EOLS) gained 50 cents to $26.44 on 537,100 shares traded Wednesday. The performance-beauty company said it will release earnings after the close of the stock market April 30. Extreme Networks Inc. (EXTR) rose 29 cents to $8.26 on 2.1 million shares traded Wednesday, nearly 1 1/2 times its average volume.
With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.
Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.
ConforMIS (CFMS) expects to register solid revenue growth on robust performance by its product lines as well as steady royalties.
Hill-Rom (HRC) consistently reports strong Core revenue growth in domestic and international markets on solid segmental performance.
Strong performance across Renal Care, Clinical Nutrition, Advanced Surgery and Acute Therapies businesses might aid Baxter (BAX) in Q1. However, lower sales at Pharmaceutical business might be a woe.
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus